Check Cap (CHEK) Earn somewhat favorable press coverage, report shows

The headlines about Check Cap (NASDAQ: CHEK) have been somewhat positive on Saturday, according to Accern Sentiment. The research agency scores the sentiment of media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks the coverage of listed companies on a scale of -1 to 1, with scores that are closest to one being the most favorable. Check Cap earned a daily sentiment score of 0.19 on the Accern scale. Accern also gave the headlines about the medical research agency an impact score of 46.933122717357 out of 100, which means that recent news coverage in the media will have little effect on the share price of the shares in the coming days.

NASDAQ shares: CHEK traded $ 0.04 on Friday and earned $ 3.51. The company had a trading volume of 34,728 shares. Check Cap has a 1-year low of $ 3.08 and a 1-year high of $ 24.00.

Check Cap (NASDAQ: CHEK) has last published its quarterly results on Friday 10 August. The medical research company reported ($ 0.70) Earnings per Share (EPS) for the quarter and outperformed consensus analysts' estimates ($ 0.82) by $ 0.12. Research analysts predict that Check Cap will publish -2.6 per share for the current year.

Several equity analysts have recently commented on the shares. Zacks Investment Research increased the share of Check Cap from a & # 39; hold & # 39; credit to a & # 39; buy & # 39; valuation and set a target price of $ 3.75 on the shares in a report on Monday, August 6. HC Wainwright set a $ 14.00 price target on Check Cap shares and gave the company a "buy" rating in a research report on Wednesday, August 1.

About Check Cap

Check-Cap Ltd., a clinical stage of medical diagnostics, is engaged in the development of a capsule-based system that uses low-dose x-rays for screening of the colon for polyps, masses & colorectal cancers in Israel to detect. The C-Scan system consists of C-Scan Cap, an X-ray scan capsule, designed to measure, collect and transmit structural information; C-Scan Track, a biocompatible unit worn on the patient's back for control of the capsule, tracking and data recording; and C-Scan View, a personal computer-based software package designed to retrieve and process clinical data from the C-Scan track, and to reconstruct and produce 3D visualization of the inner surface of the colon .

Recommended story: examples and plans for trading strategies

Insider buying and selling quarterly for Check Cap (NASDAQ: CHEK)

Receive news and ratings for Check Cap Daily – Enter your email address below to receive a concise, daily summary of the latest news and analyst reviews for Check Cap and related companies with the FREE daily email newsletter from

Source link

Leave a Reply